Comparison · NCT04535531-afab1233
SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 12
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 12. Trial comparisons, record NCT04535531-afab1233. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04535531-afab1233
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.324 | 0.282 | 0.369 | wilson | |
| Risk in group 2 | 0.197 | 0.163 | 0.236 | wilson | |
| Risk difference, group 1 minus group 2 | 0.127 | 0.07 | 0.184 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.65 | 1.31 | 2.07 | log | |
| Odds ratio, group 1 over group 2 | 1.96 | 1.44 | 2.66 | log | |
| Number needed to treat, for one more participant with the outcome on SB206 than on Placebo | 7.85 | 5.44 | 14.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SB206 | SB206 gel applied topically, once daily for 12 weeks. | 144 | 444 | OG000 |
| Group 2 | Placebo | Placebo gel applied topically, once daily for 12 weeks. | 88 | 447 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Complete Clearance of All Treatable MC at Week 12
- Description
Percent (proportion) of subjects with complete clearance of all treatable MC at Week 12. This was measured by dividing the number of subjects who showed complete clearance by the number in that treatment group (this represents our primary outcome variable).
- Time frame
- 12 Weeks
- Population
- ITT
Source ClinicalTrials.gov
Trial
- Title
- A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
- NCT number
- NCT04535531
- Phases
- PHASE3
- Conditions
- Molluscum Contagiosum
- Interventions
- SB206 10.3% berdazimer, vehicle gel
- Lead sponsor
- Novan, Inc.
- Results first posted
- 2023-01-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04535531?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04535531-afab1233